# Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct01293669` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01293669](<https://clinicaltrials.gov/study/NCT01293669>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01293669

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 440 participants.

## Technical summary

Registry record NCT01293669. Randomized; quadruple masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2012-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 440 participants (enrolled count; ClinicalTrials.gov record NCT01293669, source copy `cardio:ctgov-nct01293669-2013-09-13`, retrieved 2026-10-26)
- Start date: 2011-01 (registry gives no type) (ClinicalTrials.gov record NCT01293669, source copy `cardio:ctgov-nct01293669-2013-09-13`, retrieved 2026-10-26)
- Primary completion: 2012-01 (actual) (ClinicalTrials.gov record NCT01293669, source copy `cardio:ctgov-nct01293669-2013-09-13`, retrieved 2026-10-26)
- Completion: 2012-01 (actual) (ClinicalTrials.gov record NCT01293669, source copy `cardio:ctgov-nct01293669-2013-09-13`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01293669, source copy `cardio:ctgov-nct01293669-2013-09-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01293669-2013-09-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): TC-6987
- Intervention (Drug): Placebo
- Lead sponsor: Targacept Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 2b872a10a9231e97097e391a6fb62037a58e1d71c7f54883c31a8c4079c29779
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
